Royalty Report: Drugs, cardiac, Drug Discovery – Collection: 383599

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 20

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 20

Primary Industries

  • Drugs
  • cardiac
  • Drug Discovery
  • Disease
  • Therapeutic
  • ribonucleic acid
  • Medical
  • Proteins
  • Biotechnology
  • Diagnostic
  • nucleic acid

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 383599

License Grant
For the Product License, Licensor grants an exclusive license, with the limited right to sublicense, under the Licensed IP to research, develop, make, have made, use, sell, offer for sale, have sold, import and export Products in the Territory for therapeutic purposes.

For the Limited Right to Sublicense, the Product License is sublicensable only in connection with a sublicense of a Product to any Affiliate of Licensee or to any Third Party,

License Property
Licensor has intellectual property to advance mipomersen and related compounds targeting apoB.

Mipomersen means mipomersen sodium, including all pharmaceutically acceptable salts, solvates, hydrates, hemihydrates, metabolites, pro-drug forms, stereoisomers, enantiomers, racemates and all optically active forms thereof.

apoB means apolipoprotein B.

Product means all pharmaceutical compositions, formulations, dosage forms, delivery systems and presentations that contain Mipomersen or any Follow-On Compound as an active ingredient.

ASO Product any preparation in final form for sale by prescription, over-the-counter or any other method for any indication, including human or animal use, which contains one or more oligonucleotides or an analog thereof that  selectively modulates protein synthesis at the nucleic acid level through the binding of such oligonucleotide to a complementary sequence.

FH means familial hypercholesterolemia.

Licensed Product Patents means the Shortmer Patent, and any Patent Controlled by Isis during the Term, including any Licensor Program Patents and Joint Patents, claiming nucleic acids that hybridize to a nucleic acid molecule encoding apoB, the sequence of apoB. the specific composition of matter of a Product, or methods of using Product as a therapeutic, methods of using Product to modulate apoB, and methods of using the Product to inhibit expression of apoB- and also claiming or describing (x) nucleic acids that hybridize to a nucleic acid molecule encoding a gene target other than apoB or ( y) methods of using such nucleic acids as a therapeutic or to modulate a gene target other than apoB.

Field of Use
The field of use is to treat homozygous familial hypercholesterolemia.  Homozygous familial hypercholesterolemia is a disorder where it is hard for your body to remove LDL 'bad' cholesterol from your blood. The disease raises your chances of a heart attack at an early age, but drugs and other treatments can lower your risk.

Licensee will develop and commercialize mipomersen, Isis' lipid-lowering treatment for high risk cardiovascular patients that utilizes novel antisense technology.  Mipomersen, formerly ISIS 301012, is a lipid-lowering drug targeting apolipoprotein B-100. Currently in phase 3 development, mipomersen has been shown in phase 2 trials to reduce cholesterol and other atherogenic lipids more than 40 percent beyond reductions achieved with current standard lipid-lowering drugs, enabling more patients to achieve lipid targets.

IPSCIO Record ID: 249742

License Grant
The University grants an exclusive, even as to the University, world-wide license to research, develop, commercialize, make, have made, use, import, offer for sale and sell under the University Existing Patents and New Patents, Licensed Products and Materials in all fields during the Term, and under the Assigned Bristol-Myers Squibb Patents and Assigned BMS Technical Information, the Designated Compounds and University Materials in the Field of Use during the Term.
License Property
The patents include Composition Patents, Combination Patents, and, Universitys Existing and New Patents.

Designated Compound means BMS-201,038;  prodrugs or metabolites of BMS-201,038, to the extent any such prodrug or metabolite is covered by a composition claim in a Composition Patent; and  stereoisomers, hydrates, anhydrides, solvates, salt forms, or polymorphs of BMS-201,038 or any compounds; furthermore, in the case of a prodrug or metabolite as referred to above, the compound in question will constitute a Designated Compound hereunder only if the making, use or sale of such compound is necessary for or results from the making, use and sale of BMS-210,038 within the Field of Use.

The University completed a Phase II clinical trial of lomitapide for the treatment of patients with called homozygous familial hypercholesterolemia, or HoFH.

Field of Use
Field of Use means  monotherapy or in combination with other dyslipidemic therapies for treatment of patients with homozygous familial hypercholesterolemia; monotherapy or in combination with other dyslipidemic therapies for treatment of patients with severe hypercholesterolemia of any etiology unable to come within 15% of NCEP LDL cholesterol goal on maximal tolerated oral therapy, as determined by the patient’s prescribing physician; (c) monotherapy or in combination with other dyslipidemic therapies for treatment of patients with severe combined hyperlipidemia of any etiology unable to come within 15% of NCEP non-HDL cholesterol goal on maximal tolerated oral therapy, as determined by the patient’s prescribing physician; and (d) monotherapy or in combination with other dyslipidemic therapies for treatment of patients with severe hypertriglyceridemia unable to reduce TG<1000 on maximal tolerated therapy.

Licensee's lead compound, lomitapide, is a microsomal triglyceride transfer protein inhibitor, or MTP-I, which limits secretion of cholesterol and triglycerides from the intestines and the liver, the main sources of lipids in the body. Licensee is initially developing lomitapide as an oral, once-a-day treatment for patients with a rare genetic lipid disorder called homozygous familial hypercholesterolemia, or HoFH.  These patients are at very high risk of experiencing life threatening events at an early age as a result of extremely elevated cholesterol levels in the blood. Licensee believe that lomitapide, either on a stand-alone basis or in combination with other drugs, has the potential to help these patients achieve recommended target levels of low-density lipoprotein cholesterol, or LDL-C.

IPSCIO Record ID: 329733

License Grant
Licensor shall grant to Licensee the option with respect to Reagent Targets ( each, an Licensee Option) to obtain a non-exclusive, royalty-bearing license, including the right to sublicense, under the Licensor Non-Collaboration ASO Patent Rights to develop, make, have made, use, import, offer for sale and sell Licensee Non-Collaboration ASO Products directed to such Reagent Target in the Territory..
License Property
Licensor Non-Collaboration ASO Patent Right means all Patent Rights that are Controlled by Licensor, or any Sublicensees to whom Licensor provides data generated from the use of a Reagent ASO Compound provided to Licensor by Licensee pursuant to this Agreement and that (a) Cover inventions made by Licensor or such Sublicensee outside the course of the Collaboration and (b) either (i) include in their written specifications a description of the results of any experiment conducted using a Reagent ASO Compound provided to Licensor by Licensee pursuant to this agreement or (ii) are or were prosecuted (i.e., the results of any experiment conducted using Reagent ASO Compound provided to Licensor by Licensee pursuant to this Agreement were provided to patent office during the prosecution phase of a particular Patent Right) using any portion of the results of any experiment conducted using a Reagent ASO Compound provided to Licensor by Licensee pursuant to this Agreement.

Reagent ASO Compound means all ASO Compounds that selectively modulate protein synthesis of a Reagent Target.

ASO Compound means an oligonucleotide or an analog thereof (an oligonucleotide) that selectively modulates protein synthesis at the nucleic acid level through the binding of such oligonucleotide to a complementary sequence.

Reagent Target means a Target that is designated a Reagent Target by Licensor; provided, however, that a Reagent Target that is later designated a Validation Target or a Drug Discovery Target shall not be considered a Reagent Target after the date of such designation.

Drug Discovery Target means any Target included in the Antisense Drug Discovery Program by the Executive Committee.

Antisense Drug Discovery Program means the program of research and development of Drug Discovery ASO Compounds and Products in the Collaborative Therapeutic Areas under this Agreement and the Collaborative Research Plan.

Drug Discovery ASO Product means any preparation in final form for sale by prescription, over-the-counter or any other method for any indication, including human or animal use, which contains one or more Drug Discovery ASO Compounds.

Drug Discovery ASO Compound means an ASO Compound that selectively modulates protein synthesis of a Drug Discovery Target.

Validation Target means any Target designated by Licensor for inclusion in the Target Validation Program; provided, however, that a Validation Target that is later designated a Drug Discovery Target, shall be considered a Drug Discovery Target and not a Validation Target. Validation Targets includes Accepted Validation Targets and Rejected Validation Targets.

Target means a transcriptional unit of a gene, and any protein product of such transcriptional unit, including all splice variants.

Field of Use
Field of use is for use in gene functionalization and target validation and as therapeutic products in the field of antisense technology, including processes and techniques relating to the design, synthesis and research of antisense oligonucleotides.

Non-ASO Field means the research, development, manufacture and sale of compounds other than ASO Compounds as therapeutic or prophylactic pharmaceutical products.

ASO Field means the development, manufacture and sale of ASO Products as therapeutic or prophylactic pharmaceutical products.

IPSCIO Record ID: 258520

License Grant
The Company granted to Licensee an exclusive license in Japan, with the right to grant sub-licenses, to manufacture and commercialize the Company’s current product.
License Property
The current product is JUXTAPID, a product that contains lomitapide as the sole active ingredient.   Lomitapide is a drug used as a lipid-lowering agent .
Field of Use
The field of use is for the current marketed indication for homozygous familial hypercholesterolemia (HoFH).  Familial hypercholesterolemia is a genetic disorder. It is caused by a defect on chromosome 19. The defect makes the body unable to remove low density lipoprotein (LDL, or bad) cholesterol from the blood.

IPSCIO Record ID: 322362

License Grant
Licensor grants an exclusive, worldwide license to develop, manufacture and commercialize PCSK9.
License Property
PCSK9 is a RNAi therapeutics targeting proprotein convertase subtilisin/kexin type 9.

PCSK9 (proprotein convertase subtilisin/kexin type 9) is a protein that regulates low-density lipoprotein (LDL) receptor levels on hepatocytes; gain-of-function human mutations in PCSK9 are associated with hypercholesterolemia while loss-of-function mutations are associated with lower levels of LDL cholesterol and a reduced risk of cardiovascular disease.

Field of Use
PCSK9 is for the treatment of hypercholesterolemia and other human diseases, including inclisiran.

Hypercholesterolemia, also called high cholesterol, is the presence of high levels of cholesterol in the blood. It is a form of hyperlipidemia, high blood lipids, and hyperlipoproteinemia (elevated levels of lipoproteins in the blood).

Hypercholesterolemia is a condition characterized by very high levels of cholesterol in the blood which is known to increase the risk of coronary artery disease, the leading cause of death in the U.S. Some forms of hypercholesterolemia can be treated through dietary restrictions, lifestyle modifications (e.g., exercise and smoking cessation) and medicines such as statins.

Inclisiran is an experimental drug for the treatment of patients with atherosclerotic cardiovascular disease (ASCVD), ASCVD risk equivalents and heterozygous familial hypercholesterolemia (HeFH). It is a small interfering RNA that inhibits translation of the protein PCSK9.

IPSCIO Record ID: 344597

License Grant
Included in this license by a Third Party is a sublicense of Licensor intellectual property where the Third Party
— grants a worldwide, exclusive license under the Licensed Intellectual Property, solely to develop, make, have made, use, offer for sale, sell, and import Products in the Exclusive Field, and,
— grants a worldwide, nonexclusive license under the Licensed Intellectual Property, solely to develop, make, have made, use, offer for sale, sell, and import Products in the Nonexclusive Field.
License Property
The Third Party designs antisense drugs to treat a wide variety of diseases. Due to their gene selectivity, antisense drugs have the potential to be highly effective and less toxic than traditional drugs, and, owns or has rights in certain technology, know-how, patents and other intellectual property rights related to the design, development, manufacture and/or use of the Products.

Products means an ApoB Product, a GCCR Product and/or a GCGR Product.

ApoB means apolipoprotein B.
ApoB Product means a pharmaceutical composition comprising an ASO that targets ApoB.

GCCR means a glucocorticoid receptor.
GCCR Product means a pharmaceutical composition comprising an ASO that targets GCCR.

GCGR means a glucagon receptor.
GCGR Product means a pharmaceutical composition comprising an ASO that targets GCGR.

The patents are for
Apolipoprotien B-100,
Glucagon Receptor (GCGR) , and,
Glucocoritcoid receptor (GCCR).

Field of Use
The Exclusive Field means human therapeutics, but does not include the Nonexclusive Field.

The Nonexclusive Field means manufacturing (including analytical methods) ASOs, formulating ASOs, conducting Research on ASOs and/or supplying ASOs solely to conduct Research.

IPSCIO Record ID: 346186

License Grant
Included in this license by a Third Party is a sublicense of Licensor intellectual property where the Third Party
— grants a worldwide, exclusive license under the Licensed Intellectual Property, solely to develop, make, have made, use, offer for sale, sell, and import Products in the Exclusive Field, and,
— grants a worldwide, nonexclusive license under the Licensed Intellectual Property, solely to develop, make, have made, use, offer for sale, sell, and import Products in the Nonexclusive Field.
License Property
The Third Party designs antisense drugs to treat a wide variety of diseases. Due to their gene selectivity, antisense drugs have the potential to be highly effective and less toxic than traditional drugs, and, owns or has rights in certain technology, know-how, patents and other intellectual property rights related to the design, development, manufacture and/or use of the Products.

Products means an ApoB Product, a GCCR Product and/or a GCGR Product.

ApoB means apolipoprotein B.
ApoB Product means a pharmaceutical composition comprising an ASO that targets ApoB.

GCCR means a glucocorticoid receptor.
GCCR Product means a pharmaceutical composition comprising an ASO that targets GCCR.

GCGR means a glucagon receptor.
GCGR Product means a pharmaceutical composition comprising an ASO that targets GCGR.

The licensed patents are for
Apolipoprotien B-100,
Glucagon Receptor (GCGR) , and,
Glucocoritcoid receptor (GCCR).

Field of Use
The Exclusive Field means human therapeutics, but does not include the Nonexclusive Field.

The Nonexclusive Field means manufacturing (including analytical methods) ASOs, formulating ASOs, conducting Research on ASOs and/or supplying ASOs solely to conduct Research.

IPSCIO Record ID: 346187

License Grant
Included in this license by a Third Party is a sublicense of Licensor intellectual property where the Third Party
— grants a worldwide, exclusive license under the Licensed Intellectual Property, solely to develop, make, have made, use, offer for sale, sell, and import Products in the Exclusive Field, and,
— grants a worldwide, nonexclusive license under the Licensed Intellectual Property, solely to develop, make, have made, use, offer for sale, sell, and import Products in the Nonexclusive Field.
License Property
The Third Party designs antisense drugs to treat a wide variety of diseases. Due to their gene selectivity, antisense drugs have the potential to be highly effective and less toxic than traditional drugs, and, owns or has rights in certain technology, know-how, patents and other intellectual property rights related to the design, development, manufacture and/or use of the Products.

Products means an ApoB Product, a GCCR Product and/or a GCGR Product.

ApoB means apolipoprotein B.
ApoB Product means a pharmaceutical composition comprising an ASO that targets ApoB.

GCCR means a glucocorticoid receptor.
GCCR Product means a pharmaceutical composition comprising an ASO that targets GCCR.

GCGR means a glucagon receptor.
GCGR Product means a pharmaceutical composition comprising an ASO that targets GCGR.

The patents are for
Apolipoprotien B-100,
Glucagon Receptor (GCGR) , and,
Glucocoritcoid receptor (GCCR).

Field of Use
The Exclusive Field means human therapeutics, but does not include the Nonexclusive Field.

The Nonexclusive Field means manufacturing (including analytical methods) ASOs, formulating ASOs, conducting Research on ASOs and/or supplying ASOs solely to conduct Research.

IPSCIO Record ID: 346188

License Grant
Included in this license by a Third Party is a sublicense of Licensor intellectual property where the Third Party
— grants a worldwide, exclusive license under the Licensed Intellectual Property, solely to develop, make, have made, use, offer for sale, sell, and import Products in the Exclusive Field, and,
— grants a worldwide, nonexclusive license under the Licensed Intellectual Property, solely to develop, make, have made, use, offer for sale, sell, and import Products in the Nonexclusive Field.
License Property
The Third Party designs antisense drugs to treat a wide variety of diseases. Due to their gene selectivity, antisense drugs have the potential to be highly effective and less toxic than traditional drugs, and, owns or has rights in certain technology, know-how, patents and other intellectual property rights related to the design, development, manufacture and/or use of the Products.

The Products means an ApoB Product, a GCCR Product and/or a GCGR Product.

ApoB means apolipoprotein B.
ApoB Product means a pharmaceutical composition comprising an ASO that targets ApoB.

GCCR means a glucocorticoid receptor.
GCCR Product means a pharmaceutical composition comprising an ASO that targets GCCR.

GCGR means a glucagon receptor.
GCGR Product means a pharmaceutical composition comprising an ASO that targets GCGR.

The licensed patents are for
Apolipoprotien B-100,
Glucagon Receptor (GCGR) , and,
Glucocoritcoid receptor (GCCR).

Field of Use
The Exclusive Field means human therapeutics, but does not include the Nonexclusive Field.

The Nonexclusive Field means manufacturing (including analytical methods) ASOs, formulating ASOs, conducting Research on ASOs and/or supplying ASOs solely to conduct Research.

IPSCIO Record ID: 249743

License Grant
The German Licensor grants a non-transferable, exclusive, even as to Licensor, worldwide license, with the right to sublicense, under the Licensor Patent Rights and Know-How, to make, have made, use, sell, offer to sell, import, research, develop, commercialize and otherwise exploit Licensed Compounds and Licensed Products and Improvements. The foregoing license grant includes the right to make reference to all regulatory approvals, data, filings and correspondence, including DMFs contained within the Licensor Know-How.
License Property
Licensor has been engaged in the development of implitapide as an inhibitor of microsomal triglyceride transfer protein.

Licensed Compound means the compound known as Bay 13-9952 and identified as implitapide, and any metabolic precursors, prodrugs, isomers (chiral and otherwise), metabolites, hydrates, anhydrides, solvates, salt forms, free acids or bases, esters, amides, ethers, complexes, conjugates or polymorphs of any compounds.

Field of Use
Licensee is an emerging biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat severe lipid disorders.

Lipid disorder means a high blood levels of low-density lipoprotein (LDL) cholesterol, fats called triglycerides, or both.  Lipid disorders, such as high cholesterol, can increase the risk of heart problems, such as heart attack.

IPSCIO Record ID: 294283

License Grant
Licensor grants to the Licensee of Japan an exclusive license in the Territory to use Licensor Know-how and the Licensed Compound to develop, make, have made, import, export, use, distribute, market, promote, offer for sale and sell Licensed Product(s).

Licensor grants to an exclusive license in the Territory under the Patent Rights to develop, make, have made, import, export, use, distribute, market, promote, offer for sale and sell the Licensed Compound, solely for use as an active ingredient in Licensed Products and Licensed Products.

License Property
Licensor has Know-How and the Patent Rights relating to the antidyslipidemic compound known as BT16.

BT/6 shall mean any form, including, without limitation, any salt, hydrate, crystalline structure or the like, of the small molecule compound identified by the chemical name B,B-tetramethyl hexadecane-a, (.)-dioic acid.

BT 2000 shall mean the compounds covered by PCT Patent W098/30530 including, without limitation, B, B -tetramethyloctadecanedioic acid.

Licensed Compound shall mean BT16.

The patents include Use of alpha, omega-dicarboxylic acids as fibrinogen sinkers, and, Pharmaceutical compositions containing carboxylic acids and derivatives thereof, and, Methods of administering 3,3,14,14 terramethyl hexadecane 1,16 dioic acid.

BT16 was found to have a potent efficacy of suppressing triglyceride levels in animal and human studies. Further studies demonstrated that it has also insulin-sensitizing properties and the possibility of this compound being developed as a metabolic syndrome therapy in the future has been suggested.

Field of Use
The phase II compound BT16 is r the treatment of dyslipidemia.

Dyslipidemia is an abnormal amount of lipids (e.g. triglycerides, cholesterol and/or fat phospholipids) in the blood. In developed countries, most dyslipidemias are hyperlipidemias; that is, an elevation of lipids in the blood. This is often due to diet and lifestyle.  Dyslipidemia increases the chance of clogged arteries (atherosclerosis) and heart attacks, stroke, or other circulatory concerns, especially in smokers.

Licensee possesses extensive capabilities in the development and commercialization of pharmaceutical products in Japan and in certain countries in Asia.  Licensor is a clinical-stage pharmaceutical company engaged in discovering and developing novel RNAi interference or RNAi-based therapeutics.

IPSCIO Record ID: 344587

License Grant
Licensor grants to the Canadian Licensee an exclusive, worldwide license under the Licensor Product-Specific Technology Patents and the Joint Patents to any Product-Specific Technology and under the Licensor Core Technology Patents, in each case solely to develop, make, have made, use, sell, offer for sale, have sold and import Products.
License Property
Licensor is a biopharmaceutical company exploiting proprietary RNA-based drug discovery technologies to identify and commercialize novel drugs.

Antisense Compound means an oligomeric compound or analog, mimic or mimetic thereof having a sequence that is partially or wholly complementary to the sequence of a messenger RNA (pre-mRNA or mRNA), viral RNA, or noncoding RNA that directly modulates RNA expression.

Product means a pharmaceutical preparation comprising any single TS ASO or Tandem selected by Licensee. After the Project Plan has been completed, the Parties will append to this Agreement the specific sequence and chemistry of each TS ASO which constitutes the active pharmaceutical ingredient in each Product.

TS ASO means a single-stranded oligonucleotide or an analog thereof that hybridizes to TS mRNA using Watson-Crick base pairing and inhibits production of TS via an RNase-H mechanism.

1. U.S. Patent No. 6,001,1653
2. PCT Publication No. WO 93/13121
3. U.S. Patent. 5,914,396
4. U.S. Patent 61451,991
5. U.S. Patent No. 6,166,197
6. U.S. Patent No. 51919,619
7. U.S. Patent No. 5,962,425
8. U.S. Patent No. 6,143,881
9. U.S. Patent No. 5,969,116
10. U.S. Patent No. 6,346,614
11. U.S. Patent No. 6,399,754
12. U.S. Patent No. 6,326,199

Field of Use
The field of use is the identification of a lead TS ASO targeted to inhibit Thymidylate Synthase.

The drug is an antisense inhibitor of thymidylate synthase (TS), a well-known drug target that protects cancer cells from the effects of several chemotherapy treatments. In preclinical studies, antisense inhibition of TS suppressed human tumor cell growth and overcame tumor cell resistance to marketed TS-targeted drugs.

TS is an important target in a wide variety of cancers including, colorectal, breast, stomach, esophageal, head and neck cancers, and mesothelioma; it is of increasing importance in non-small cell lung cancer. In addition to interfering with the effectiveness of chemotherapy, the TS gene may also participate in causing cancer. TS is a target for several chemotherapy agents, including 5-fluorouracil (5-FU), pemetrexed (Alimta®), and raltitrexed (Tomudex®).

IPSCIO Record ID: 314344

License Grant
Licensor hereby grants to Licensee an exclusive, sublicensable, royalty-bearing license in the Territory under the Licensed Patents Controlled by Licensor to make, have made, use, Sell, have Sold, offer for Sale and import and export Licensed Products and to practice Licensed Patents, in each case in the Field of Use. Licensee acknowledges that the Licensed Patents licensed to Licensor pursuant to the University Agreement exist only in certain countries in the Territory.
License Property
Patent Rights shall mean the Valid Claims of the following United States patents and patent applications

#5,883,294 – Selective thyroid hormone analogs
#6,107,517 – Thyroid hormone analogues and methods for their preparation

Licensed Product shall mean any Product, including, without limitation, a Product for use or used in practicing a Licensed Method and any Product made by practicing a Licensed Method, the manufacture, use, Sale, offer for Sale or import of which, but for the license granted in this Agreement, would infringe, or contribute to, or induce the infringement of, any Licensed Patents in any country were they issued at or prior to the time of the infringing activity in that country.

Product shall mean any kit, article of manufacture, composition of matter, material, compound, component or product.

Licensed Patents shall mean (i) the Patent Rights; (ii) any other patents and patent applications that are now or hereafter Controlled by Licensor that are (a) necessary to make, use or sell the composition of matter of any compound, or to practice a method, claimed by the Patent Rights in subsection (i), or (b) necessary to make or use the composition of matter of any intermediates used to make the foregoing compounds; and (iii) any patents and patent applications on inventions made by Licensor during its participation on the Steering Committee, in each case including any foreign counterparts thereof, and any continuations, continuations-in-part, divisions, re-issues, additions, reexaminations, renewals and extensions thereof, and any patents issuing from any such patent applications in any jurisdiction in the Territory. In no event shall the Licensed Patents include any patents or patent applications Controlled by Licensor that claim any methods of manufacturing or formulations of the compositions of matter claimed by the Patent Rights, unless such patents and patent applications are described in (i) or (ii).

Licensor is a company that licenses certain compounds for all human therapeutic applications including the treatment of lipid disorders and obesity.

Field of Use
Field of Use shall mean the use of Licensed Product or Licensed Method for all human therapeutic applications, including, but not limited to, the treatment of hyperlipidemia, obesity and diabetes. The Field of Use specifically excludes all uses and applications other than human therapeutic applications.

The new compound is called QRX-431 and is designed to treat lipid abnormalities involving LDL-cholesterol and lipoprotein-a, both recognized as risk factors for cardiovascular disease.

The Licensee has acquired licensing rights for a treatment of lipid disorders.

IPSCIO Record ID: 301197

License Grant
Licensor grants the Licensee of Japan exclusive rights to NEXLETOL and NEXLIZET tablet development and commercialization in Japan.
License Property
NEXLETOL and NEXLIZE are cost-effective, oral, once-daily, non-statin LDL-cholesterol (LDL-C) lowering medicines.
Field of Use
The field of use is for hypercholesterolemia patients in Japan.  Hypercholesterolemia, also called high cholesterol, is the presence of high levels of cholesterol in the blood. It is a form of hyperlipidemia, high blood lipids, and hyperlipoproteinemia (elevated levels of lipoproteins in the blood).  High cholesterol can limit blood flow, increasing risk of heart attack or stroke.

IPSCIO Record ID: 279309

License Grant
Licensor grants to the Licensee of Puerto Rico an exclusive license, with the right to sublicense, under the Licensor Compound Patents, Other Licensor Patents and Licensor Know-How, to research, develop, make, have made, use, sell, have sold, offer for sale and import the Compound and Products in the Field in the Territory.

Licensor grants a non-exclusive, royalty free license to use Licensors corporate Trademarks solely for purposes of Commercializing Products, which license shall terminate upon the expiration or earlier termination of this Agreement for any reason.

License Property
Licensor is engaged in manufacturing, research and development of pharmaceutical products and is currently engaged in the development of AGI-1067.  

Compound means AGI-1067, which is chemically defined as Butanedioic acid, including its pharmacologically acceptable salts, solvates, hydrates, hemihydrates, polymorphs, metabolites; free base forms, pro-drugs, esters, tautomers and if applicable, any isomers, stereoisomers, racemates, enantiomers and all optically active forms thereof.

AGI-1067 is a novel vascular protectant, anti-inflammatory drug and mild antiplatelet agent for treatment of atherosclerosis.
Atherosclerosis is a disease in which the inside of an artery narrows due to the build up of plaque.

Field of Use
Licensee is engaged in the research, development, manufacture and marketing of pharmaceutical products.  AGI-1067 is designed to benefit patients with coronary heart disease (CHD), which is atherosclerosis of the blood vessels of the heart.   Atherosclerosis is a common disease that results from inflammation and the buildup of plaque in arterial blood vessel walls.

IPSCIO Record ID: 300

License Grant
The University grants the Licensee an exclusive right and license to practice, commercialize and otherwise exploit the Licensed Patents and grants the exclusive right and license to make, have made, research, develop, use, lease, offer to sell, sell, import and export Licensed Products, within the Licensed Field of Use in the Licensed Territory during the term.
The Licensee has the right to grant sublicenses.
License Property
The licensee covers AEM-28 and certain analogs.

U.S. Patent No. 6,156,727. Anti-atherosclerotic peptides and a transgenic mouse model of atherosclerosis.
U.S. Patent No 6,506,880. Synthetic peptides that enhance atherogenic lipoprotein uptake and lower plasma cholesterol.
U.S. Patent No. 7,653,771. Synthetic single domain polypeptides mimicking apolipoprotien F, Anantharamaiah.

Apolipoprotein E (Apo E) is a 299 amino acid protein that plays an important role in lipoprotein metabolism. AEM-28 is a 28 amino acid mimetic of Apo E that contains a domain that anchors into a lipoprotein surface while also providing the Apo E binding domain that is removed by heparin sulfate receptors in the liver. AEM-28 as an Apo E mimetic has the potential to restore the ability of atherogenic lipoproteins to be cleared from the plasma, completing the reverse cholesterol transport pathway, and thereby reducing cardiovascular risk. This is an important mechanism of action for AEM-28. For patients that lack LDL receptors (Homozygous Familial Hypercholesterolemia or HoFH), have Severe Refractory Hypercholesterolemia, or have acute coronary syndrome, AEM-28 may provide a therapeutic solution.

Field of Use
Licensed Field of Use means any and all diagnostic, therapeutic and prophylactic uses in all fields of use, and for all indications except diseases of the eye.

IPSCIO Record ID: 301257

License Grant
Licensor and Licensee will design and identify morpholino and morpholino peptide conjugate splice switching oligomers that modulate the splicing of Licensor-Licensee Exclusive Targets and the Licensee Exclusive Targets. For each Licensor-Licensee Exclusive Target, Licensee will provide Splicing Modulators to be tested for their ability to modulate splicing.

General Overview. Licensor and Licensee will identify and develop Splicing Modulators that modulate the splicing of Licensor-Licensee Exclusive Targets and Licensee Exclusive Targets, as more specifically described in the Research Plan.

Licensor grants to Licensee an exclusive worldwide license to the Splicing Patents solely to research, develop, make and have made, offer for sale, sell, import and export Licensee Exclusive Products.

License Property
Product means an Licensor-Licensee Exclusive Product or an Licensee Exclusive Product, or both.

Licensor-Licensee Exclusive Products are a fixed pool of exclusive Gene Targets for research and development efforts to discover and develop Products that modify such exclusive Gene Targets to develop Splicing Modulators.

Licensee owns or controls certain patents related to morpholino chemistry.

Licensor-Licensee Exclusive Product means a Splicing Modulator that modulates an Licensor-Licensee Exclusive Target and that is Covered by the Licensee Patents and/or an Licensor Invention Patent.

Licensee Exclusive Product means a Splicing Modulator that modulates an Licensee Exclusive Target and is Covered by the Splicing Patents and/or an Licensee Invention Patent.

Splicing Modulator means an oligonucleotide or analog thereof that selectively modulates RNA Splicing or polyadenylation by a non-Rnase dependent mechanism at the nucleic acid level by specifically binding to the sequence of a selected messenger or viral ribonucleic acid (RNA) by base-pairing, thus causing a selective pattern of gene expression.

Licensee Patents means the patent(s) listed.
5,142,047 – Uncharged polynucleotide-binding polymers

Splicing Patents means the Isis Splicing Patents and the Licensor Splicing Patents.

Licensor Splicing Patents means the patent(s) listed.
5,976,879 – Antisense oligonucleotides which combat aberrant splicing and methods of using the same

Isis Splicing Patents means the patent(s) listed.
6,210,892 – Alteration of cellular behavior by antisense modulation of mRNA processing

Licensee Invention Patent and/or Licensor Invention Patent has the meaning depending how any Inventions are made under the Research Plan will define if it is an Licensor Invention or an Licensee Invention, as the case may be, and Patents claiming such Inventions will be Licensor Invention Patents or Licensee Invention Patents, respectively.

Licensor-Licensee Exclusive Target also known as Gene Targets that are selected for their research and development efforts.
List of the five selected Targets
TNFRl
TNFR2
He.r2
BCL-X
CD28

Licensee Exclusive Target also known as Gene Targets that are selected for their research and development efforts.
List of the five selected Targets
PDl
CTLA4
TGF beta
P53
IL23

Field of Use
This agreement pertains to the drug industry related to RNA splicing in the areas of drug discovery and medicinal chemistry,

IPSCIO Record ID: 286054

License Grant
University grants Licensee an exclusive (even as to University), worldwide, irrevocable, non-transferable  license in the Biodiagnostics Field, with the right to sublicense, under the University Patent Rights, to make, have made, use, sell, offer for sale, export and import Licensed Products within the Biodiagnostics Field.

University grants Licensee an exclusive (even as to University), worldwide, irrevocable, non-transferable  license in the Biodiagnostics Field, with the right to sublicense, under the Joint Patent Rights, to make, have made, use, sell, offer for sale, export and import Licensed Products within the Biodiagnostics Field.

University grants Licensee a nonexclusive, worldwide, irrevocable, non-transferable license in the Biodiagnostics Field, with the right to sublicense, to use the Technical Information to design, develop, manufacture, have manufactured, sell, offer for sale, import, and export the Licensed Products within the Biodiagnostics Field.

Each party acknowledges that the other party is a co-owner of an equal and undivided interest in and to the Joint Patent Rights.

License Property
University Patent Rights means
6,709,825 – Nanoparticles having oligonucleotides attached thereto and uses therefor
6,902,895 – Nanoparticles having oligonucleotides attached thereto and uses therefor
7,115,688 – Nanoparticles with polymer shells

Joint Patent Rights means
6361944 – Nanoparticles Having Oligonucleotides Attached Thereto And Uses Therefore

Biobarcode Technology means analysis where oligonucleotides act as surrogate targets or reporter molecules.

Nanoparticle Technology means any technology in the Biodiagnostics Field involving a particle where no single dimension is greater than 100 nm.

Field of Use
Biodiagnostics Field means the qualitative or quantitative in vitro analysis, testing, measurement, or detection of the following specific field subset and target combinations (including products that incorporate in vivo harvesting of test samples for ex vivo testing)
Biodiagnostics Field Subsets – Targets

Human and animal testing (Includes pharmaceutical and biotechnology discovery and development) –
Nucleic acids, proteins, peptides, amino acids, metabolites, therapeutic drugs, drugs of abuse, hormones, sugars, lipids and lipoproteins
Plants – Nucleic acids, proteins, peptides, phytotoxins
Environmental – Pathogens, toxins and biological contaminants

The Biodiagnostics Field excludes the following subject matter and all Biodiagnostics Field applications thereof
(a) therapeutics (including in vitro and in vivo therapy and controlling, modulating, or otherwise affecting gene expression);
(b) technology relating to or derived from dip-pen nanolithography;
(c) environmental applications other than as set forth above;
(d) prismatic particles (including methods of manufacture and uses thereof); and
(e) coordination polymers (including methods of manufacture and uses thereof).
For purposes of clarity, other than with respect to Biobarcode Technology or an Invention where the Licensed Product itself is the surrogate for the target listed above, the term “detection” means the detection of the actual target listed above and not the detection of a surrogate, not listed above, for the target.

IPSCIO Record ID: 230770

License Grant
For the exclusive licenses, Licensor grants
– during the Research Term, the exclusive worldwide right and license to use the Licensor Technology to the extent necessary to conduct the Research Program;
– during the Evaluation Tail, the exclusive worldwide right and license to use the Licensor Technology to the extent necessary to determine whether any of the then identified Hit Compounds or Activator Compounds can become Lead Compounds and to further screen and conduct selectivity testing of any Lead Compounds identified in the Research Term for the purpose of determining whether Licensee will select any such Lead Compounds as Development Candidates;
– the exclusive right and license to use the Licensor Technology to develop and have developed Agreement Compounds and Products and to make, have made, use, import, export, market, offer for sale, sell and have sold Products in the Territory for use in the Licensee Field; and
– if Licensee exercises the Licensee Option with respect to any Option Compound, the exclusive right and license to use the Licensor Technology to develop and have developed such Option Compound and any Option Product containing such Option Compound and to make, have made, use, import, export, market, offer for sale, sell and have sold such Option Products in the Territory for use in the Licensee Field.
License Property
Licensor possesses scientific and proprietary technology and data and resources relating to the Hedgehog Pathway.

The Product shall mean any final dosage form of a pharmaceutical product containing a Development Compound, independent of indication, route of administration, or dosage strength or form.

Agreement Protein shall mean the Hedgehog protein,as described in U.S. Patent #6,384,192, and any proteins and polypeptides, included in the Licensor Technology, which have preferential binding affinity foe the Hedgehog proteins natural receptor.

Compound shall mean a small molecule or macromolecule compound (including. without limitation, the Agreement Protein), together with all complexes, mixtures and other combinations, pro~drugs, metabolites, enantiomers, salt forms, racemates and isomers thereof.

Field of Use
Licensee desires to obtain a license to this proprietary technology to further develop and commercialize pharmaceutical products for the treatment of, among other diseases, neurodegenerative diseases and neuropathies.

Licensors Field shall mean the topical administration of Activator Compounds or Agreement Protein for the promotion of  hair growth and the Local Administration of Activator Compounds for the treatment of cardiovascular diseases, including but not limited to the use of an Activator Compound coated on a cardiovascular stent.

Licensees Field shall mean the treatment or prevention of diseases and/or disorders in humans.

The Research Field means the discovery, characterization, design, development and commercialization of Compounds for the treatment or prevention of neurodegenerative diseases or conditions and/or neuropathies wherein such Compounds exert such therapeutic, prophylactic or other beneficial effects are achieved, in whole or in material part, through Pathway Activator Activity.

IPSCIO Record ID: 230823

License Grant
Licensor grants to an irrevocable, worldwide, sublicensable, exclusive license to the Technology to make, have made, use, import, export, distribute, sell, offer to sell and have sold the Drug in the Field and to make, have made, use, import, export, distribute, sell, offer to sell and have sold products incorporating or utilizing the Drug and/or the Technology in the Field, practice methods covered thereby, and otherwise to commercialize and exploit, the Drug and/or the Technology in the Field.
License Property
Licensor has developed technology relating to antisense compounds, including Resten NGâ„¢.

Resten-NG is a third-generation NeuGene® antisense compound, is designed to address the underlying genetic mechanism that leads to restenosis. The result is that this compound can selectively target multiple aspects of the restenosis response, specifically cellular proliferation, secretion of matrix proteins and inflammation, potentially without impeding vascular healing.  Restenosis is the renarrowing or reclogging of arteries following balloon angioplasty or placement of a stent.  Resten-NG is currently in Phase II clinical trials.

Compound means any drug as defined in the Federal Food, Drug and Cosmetic Act, as amended, not licensed hereunder and all derivatives and analogues of such drug, any biological product as defined in the Public Health Service Act, as amended, not licensed hereunder and all derivatives and analogues of such biological product and the antisense compounds not licensed hereunder.

The patents include morpholino-based polymers, sequence-specific polynucleotide-binding polymers, antisense oligonucleotides, and, method for blocking proliferation of a non-transformed cell in vivo or in vitro.

Field of Use
Field means the treatment of vascular disease only in conjunction with the use of a stent, balloon, catheter or any other medical device (other than a medical device providing for systemic application). The parties acknowledge that the Field docs not include the treatment of hypertension or congestive heart failure except as may occur through the treatment of restenosis or atherosclerosis.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.